Document is current
Any future updates will be listed below
-
Authors
Zhao, Yayi
Amorrortu, Rossybelle P.
Stewart, Sandra C.
Ghia, Kavita M.
Williams, Vonetta L.
Sondak, Vernon K.
Tsai, Kenneth Y.
Pinilla-Ibarz, Javier
Chavez, Julio C.
Rollison, Dana E.
-
Funding
Funding for this research was provided by:
Moffitt’s Cancer Center Support Grant (P30-CA076292, P30-CA076292)
- License Information
-
More Information
Article History
Received: 12 May 2023
Accepted: 27 October 2023
First Online: 9 November 2023
Declarations
:
: The Moffitt Scientific Review Committee reviewed the study protocol (MCC#22268) and determined that the study met the definition of non-human subjects research and did not require IRB approval. All methods were performed in accordance with the relevant guidelines and regulations.
: Not applicable.
: Financial interests: Rossybelle P. Amorrortu, Yayi Zhao, Sandra C. Stewart, Kavita M. Ghia, Dr. Vonetta L. Williams, and Dr. Ken Tsai declare they have no financial interests. Dr. Vernon K. Sondak is a compensated consultant for Merck, Novartis, Regeneron, and Iovance.Non-financial interests: Dr. Dana Rollison serves on the Board of Directors for NanoString Technologies, Inc. Dr. Vernon K. Sondak serves on the Advisory Boards for BMS, Novartis and Eisai. Dr. Javier Pinilla-Ibarz is a compensated consultant for Janssen, AbbVie, AstraZeneca, Takeda, Novartis, TG Therapeutics, MEI, and BeiGene. Dr. Julio Chavez is a paid consultant for Morphosys, Kite Pharma, Amgen, AbbVie, BeiGene, AstraZeneca, ADC Therapeutics, TG Therapeutics, and Novartis Pharmaceutical Corp.
